The success rate of subcutaneous transplantation of pancreatic islets has been extremely low. Insufficient oxygen supply to the grafted islets is one possible major obstacle to the preservation of graft function. This study attempted to use basic fibroblast growth factor (bFGF) in subcutaneous transplantation to induce neovascularization and a sufficient blood flow around the space formed for grafted islets in the subcutaneous tissues. A bFGF-releasing device was designed enclosing bFGF in a polyethylene terephthalate mesh bag coated with polyvinylalcohol hydrogel. In the vascularized group (n = 5), two bFGF-releasing devices were implanted bilaterally into the subcutaneous tissue of the back of streptozotocin-induced diabetic Lewis rats. One week after implantation, isolated rat islets (5000) were syngeneically transplanted subcutaneously after the removal of the devices. In the control group (n = 5), no devices were implanted and the same number of rat islets was transplanted directly. One week after the implantation of the devices into the test animals, a thick, well-vascularized capsule was observed in the subcutaneous site. All vascularized recipient rats showed significant decreases in nonfasting blood glucose and maintained normoglycemia for more than 1 month after islet transplantation. However, in the control group, all rats failed to achieve normoglycemia after transplantation. This study provides evidence that the subcutaneous tissue is a promising site for pancre atic islet transplantation, offering convincing advantages in acceptability for diabetic recipients. Establish ment of this subcutaneous islet transplantation technique will afford some new perspectives on successful clinical islet transplantation.
INTRODUCTION
Various sites for pancreatic islet transplantation have been addressed to investigate a possibility to achieve normal glucose control of diabetic recipient animals.
Subcutaneous tissues, peritoneal space, portal venous system in the liver, subcapsular space of the kidney, in tramuscular space, testis, intrathecal space, etc., were examined for transplantation sites on experimental islet transplantation previously (1, 6, 13) . Recently, in clinical trials of pancreatic islet transplantation, transplantation into an intraportal site has become a standard procedure with its superior outcome in insulin-independent rate during the posttransplant period (2, 14) . However, islet transplantation into an intraportal site involves some critical problems on clinical islet transplanatation such as a loss of function of islet grafts in the early phases of the posttransplant period. It has been pointed out that nonspecific inflammatory responses caused by activated hepatic macrophages and other cells may damage intra portally grafted islets (5, 9, 14) . Hence, we believe that an optimal site for islet transplantation would not be limited to an intraportal site when a transplantation site could be reconstructed as a suitable environment for grafted islets. Establishment of an optimal site for islet transplantation would necessarily raise the acceptability of this type of therapy for patients with type I diabetes mellitus.
The subcutaneous site has some advantages, such as easy access with a minimally invasive procedure and a capability to retrieve the grafts easily. However, the suc cess rate of subcutaneous transplantation of pancreatic islets has been extremely low. A previous report (6) sug gests poor vascular distribution in the subcutaneous tis-sues is a possible cause of the failure in subcutaneously grafted islets after the implantation. There have been few reports regarding a successful outcome after subcu taneous islet transplantation (4, 7, 15) . A first encourag ing report, employing polyglycolic acid (PGA) sheet de vices implanted into subcutaneous tissues of a recipient mouse, demonstrates that the induction of angiogenesis to form neovascularization at a subcutaneous bransplantation site improves the function of islet grafts on a dia betic mouse model (4) . In a recent report, using a vascu larizing ported device implanted into diabetic nude mice subcutaneously, grafted islets in this device could sur vive and function after implantation (15) . However, it is necessary to clarify whether the vascularized structure in the transplantation site could affect the prevention of early failure in considerable numbers of subcutaneously transplanted islets to achieve normoglycemia during the early phase of the posttransplant period. If a transplanta tion site could be reconstructed as a suitable environ ment in which grafted islets could function, a much larger number of islets would survive for longer periods after transplantation. For this purpose, another innova tive approach for modifying the subcutaneous tissues would be needed to establish a method for subcutaneous islet transplantation.
We focused on basic fibroblast growth factor (bFGF) as an inducing factor of angiogenesis (10, 11) . Induction of angiogenesis in the subcutaneous site with growth factor would be a potential method to reconstruct subcu taneous tissues with neovascularized structure. In this study, we attempted to modify subcutaneous tissues to induce neovascularization and a sufficient blood flow around the space formed for grafted islets in the subcuta neous tissues employing bFGF-releasing device.
MATERIALS AND METHODS

Male Lewis rats (Shimizu Laboratory Supplies Co.
Ltd., Kyoto, Japan), from 8 to 10 weeks old, weighing Recipient diabetic rats were divided into two groups.
In the group receiving pretreatment for vascularization (n = 5), two bFGF-releasing devices were implanted bilat erally into the subcutaneous tissue of the back through a skin incision. One week after implantation, isolated rat islets (5000) were syngeneically transplanted into the sub cutaneous space after the removal of the devices. In the control group (« = 5), the devices were not used but the same number of rat islets was transplanted directly into the subcutaneous tissue on both sides of the back. In both groups, the nonfasting blood glucose levels and the body weights were measured every day for 2 weeks and twice a week for an extended period after transplantation.
Results are expressed as mean ± SD. The paired Stu dent's /-test was performed for the statistical evaluation of data at different time points. Significance was defined at the 0.05 level.
RESULTS
One week after implantation of a bFGF-releasing de vice to the recipient rats, a thick, richly vascularized capsule was observed in the subcutaneous tissues, and a little yellowish serous fluid had collected within the cap sule. There was no evidence of adhesion to the device and the device was easily removed. In the histological study, there were a large number of capillary vessels in the vascularized capsules in subcutaneous tissues around the bFGF-releasing devices (Fig. 1) . Figure 2A shows the change in the nonfasting blood glucose levels of the recipient rats after subcutaneous islet iso-transplantation. All of the rats in the group given pretreatment to induce vascularization showed significant decreases in nonfasting blood glucose and achieved normoglycemia (<250 mg/dl) within 3 weeks glucose levels of the recipient rats decreased slightly once within a few days in some cases, but was already elevated by day 7. All of these rats failed to achieve normoglycemia after transplantation (pretransplant level: 538.8 ± 50.8 mg/dl; the level 4 weeks after transplant: 522.8 ±43.3 mg/dl).
The body weights of the recipient rats are expressed in Figure 2B . In the pretreated group, body weight sig nificantly increased soon after subcutaneous islet trans plantation in all rats (pretransplant level: 255.4 ± 25.0 g; the weight 4 weeks after transplant: 327.0 ± 26.2 g, p < 0.01). However, body weights in the control group re mained unchanged (pretransplant level: 259.6 ± 17.9 g; the weight 4 weeks after transplant: 251.4 ± 31.8 g).
DISCUSSION
In this study, we investigated the efficacy to recon struct a subcutaneous transplantation site to form vascu larized sutructure and to achieve a sufficient blood sup ply in the space formed for grafted islets in the subcutaneous tissues using a bFGF-releasing device. Thompson and colleagues (16) , regarding the induction of organoid neovascular structure formation with bFGF, served to establish our new method. They demonstrated that a collagen-coated polytetrafluoroethylene sponge bonded with acidic FGF and implanted in the peritoneal cavity of a rat exhibited substantial new vessel growth from organs such as liver and spleen to which the im plant is attached. However, this method seems to present difficulties in removal of the implant when necessary because of the risk of injury to these organs (16) . We devised a novel system of using bFGF in subcutaneous transplantation as a factor to induce neovascularized tis sue, which might affect the function of the grafted islets.
All recipient rats in the group pretreated with bFGFreleasing devices clearly underwent changes in the sub cutaneous tissues around the implanted devices, result ing in the formation of richly vascularized tissues. It is suggested that bFGF played an important role in the in duction of neovascularization in the subcutaneous site.
The fact that the function of the islets transplanted into this subcutaneous site was improved in the recipient rats in which neovascularization had taken place also sug gests that these richly vascularized subcutaneous tissues are an appropriate site for isolated islet cells. This study demonstrated that all recipient rats in the group with neovascularization achieved normoglycemia after trans plantation, thus indicating the reliability and reproduc ibility of this method.
It has been suggested that the process of revascular ization in transplanted islet graft is of crucial importance for the preservation of function during the early phase of the posttransplantation period (3, 8, 17 form a well-vascularized capsule in the transplantation site. We suggested that the formation of capillary net work around the space formed before implantation of islets could be beneficial to the early reperfusion of iso lated islets, leading to the prevention of grafted islet loss. Whether the islets grafted into this newly estab lished subcutaneous site could function for longer peri ods after transplantation is under further investigation. We are strongly interested in what change will occur in a microenvironment around the islets at this site.
In conclusion, this study provides evidence that the subcutaneous tissues can be utilized as a site for pancre atic islet transplantation. Establishment of this new method for successful subcutaneous islet transplantation will provide some new perspectives on future clinical islet transplantation.
